目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T28109 | |||
MRX-I, a monoamine oxidase-A (MAO-A) Inhibitor, is used potentially for the treatment of acute bacterial skin. | |||
T68177 | |||
MDL-72394 is a selective inhibitor of monoamine oxidase (MAO-A). | |||
T68593 | |||
Almoxatone, also known as MD 780236, is a monoamine oxidase (MAO) inhibitor. | |||
T72892 | |||
AChE/MAO-IN-1 是一种有效的AChE、MAO-A 和MAO-B 抑制剂,对人 AChE、MAO-B 和MAO-A 的IC50分别为 0.0248、0.0409 和 0.1108 μM。 | |||
T33268 | |||
Mebanazine oxalate 是一种有效的单胺氧化酶 (MAO) 抑制剂。Mebanazine oxalate 可用于抑郁症的研究。 | |||
T10154 | Others | ||
MAO-B-IN-1 is a monoamine oxidase B inhibitor and can be used for the research of neurological diseases. | |||
T27523 | |||
H77-77, a monoamine oxidase (MAO) inhibitor, produces a pronounced protection against phenelzine within the serotonergic and noradrenergic neurons in rats. | |||
T79229 | Monoamine Oxidase | ||
ETAP为一种既抑制MAO-A也抑制MAO-B的化合物,展现出抗抑郁样活性,可应用于重度抑郁症的研究领域。 | |||
T61463 | |||
Monoamine oxidase/Aromatase-IN-1 (compound 2q) is a potent dual inhibitor of monoamine oxidase (MAO) and aromatase, with IC50 values of 39 nM and 31 nM for MAO-B and aromatase, respectively. It holds significant potential for research in neurological disorders and breast cancer [1]. | |||
T61321 | |||
MAO-B-IN-12 (Compound 16c) is a highly effective inhibitor of monoamine oxidase B (MAO-B), displaying significant potency with an IC50 value of 1.3 μM. Additionally, MAO-B-IN-12 exhibits notable neuroprotective activity [1]. |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPK-01419 | Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 | ||
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner.
|
|||||
TMPK-01426 | Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner.
|
|||||
TMPK-01422 | Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Peptide Ready HLA-A*02:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner.
|
|||||
TMPK-01425 | Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 | ||
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner.
|
|||||
TMPK-01410 | Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner.
|
|||||
TMPK-01420 | Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner.
|
|||||
TMPK-01421 | Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 | ||
HLA-A*02:01&B2M&Peptide ready Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner.
|
|||||
TMPK-01409 | Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 | ||
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner.
|
|||||
TMPK-01415 | APC-equivalent Peptide Ready HLA-A*02:01&B2M Tetramer Protein, Human, MHC (His) | Human | HEK293 | ||
Peptide Ready HLA-A*02:01&B2M Tetramer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner.
|
|||||
TMPK-01442 | HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled | Human | HEK293 | ||
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth.
|
|||||
TMPK-01408 | HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | E. coli | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
|
|||||
TMPK-01480 | HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 | ||
Survivin (also known as BIRC5) is an evolutionarily conserved eukaryotic protein that is essential for cell division and can inhibit cell death. Normally it is only expressed in actively proliferating cells, but is upregulated in most, if not all cancers; consequently, it has received significant attention as a potential oncotherapeutic target.
|
|||||
TMPK-01539 | HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 | ||
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
|
|||||
TMPK-01473 | HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 | ||
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa.
|
|||||
TMPK-01484 | HLA-A*02:03&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-01529 | HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
|
|||||
TMPK-01458 | HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
|
|||||
TMPK-01463 | HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
|
|||||
TMPK-01527 | HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
|
|||||
TMPK-01477 | HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-01500 | HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
|
|||||
TMPK-01445 | HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 | ||
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors.
|
|||||
TMPK-01401 | HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi) | Human | E. coli | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
|
|||||
TMPK-01429 | HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated | Human | E. coli | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
|
|||||
TMPK-01488 | HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
|
|||||
TMPK-01433 | HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
|
|||||
TMPK-01518 | HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
|
|||||
TMPK-01449 | HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein, Human, MHC (E. coli, His & Avi) | Human | E. coli | ||
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
|
|||||
TMPK-01510 | HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
|
|||||
TMPK-01493 | HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa.
|
|||||
TMPK-01455 | HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited.
|
|||||
TMPK-01474 | HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa.
|
|||||
TMPK-01530 | HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 | ||
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of malignant tumors that highly express LMP2.
|
|||||
TMPK-01403 | HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi) | Human | E. coli | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
|
|||||
TMPK-01448 | HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein, Human, MHC (E. coli, His & Avi) | Human | E. coli | ||
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
|
|||||
TMPK-01427 | HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | E. coli | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
|
|||||
TMPK-01434 | HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
|
|||||
TMPK-01444 | HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors.
|
|||||
TMPK-01461 | HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
|
|||||
TMPK-01525 | HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
|
|||||
TMPK-01417 | HLA-A*02:03&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled | Human | HEK293 | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-01479 | HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
|
|||||
TMPK-01519 | HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-01446 | HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors.
|
|||||
TMPK-01494 | HLA-A*01:01&B2M&CT83 (NTDNNLAVY) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Cancer/testis antigens 83 (CT83), also called KK-LC-1 or CXorf61, recognized by cytotoxic T lymphocytes (CTL), has become a promising target for immunotherapy.
|
|||||
TMPK-01513 | HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 | ||
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
|
|||||
TMPK-01399 | HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | E. coli | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
|
|||||
TMPK-01404 | HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated | Human | E. coli | ||
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
|
|||||
TMPK-01520 | HLA-A*02:01&B2M&AFP (PLFQVPEPV) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 | ||
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.
|
|||||
TMPK-01481 | HLA-A*24:02&B2M&Survivin 2B (AYACNTSTL) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 | ||
Survivin-2B, a known splice variant of survivin, has been reported to promote cell death in some cancer cells, although it keeps prosurvival function in others.survivin-2B promoted autophagy and further regulated cell death by accumulating and stabilizing IKK alpha in the nucleus.
|